Medicine
Genetic Predisposition to Statin-Induced Myopathy
Quick fact
A common variant in the SLCO1B1 gene increases the risk of statin-induced myopathy by up to 4.5-fold for simvastatin.
Why this is interesting
Millions take statins to lower cholesterol, yet some experience muscle pain while others don't—could your DNA be the deciding factor?
Read the full explanation
Understanding Genetic Predisposition to Statin-Induced Myopathy
Statins are a class of drugs that lower cholesterol by inhibiting HMG-CoA reductase, an enzyme in the liver. They work well, but some people develop muscle-related side effects, from mild aches to severe myopathy. Why? The drug has to reach the liver to work, but it also circulates in the blood. Our body has transport proteins that move drugs into and out of cells. If a specific transporter (OATP1B1) that pulls statins into the liver is less effective due to a genetic variation, statins stay longer in the bloodstream, exposing muscles to higher concentrations, which can cause damage.
A deeper explanation
The most well-studied genetic factor is a single nucleotide polymorphism (SNP) in the SLCO1B1 gene, rs4149056. SLCO1B1 encodes the organic anion transporting polypeptide OATP1B1, which is expressed on the membrane of liver cells and is responsible for the hepatic uptake of many statins, including simvastatin and atorvastatin. The variant reduces transport activity, leading to higher plasma concentrations of the statin. This increased systemic exposure raises the risk of muscle toxicity. Other genes, such as CYP3A4 and CYP3A5, are involved in metabolizing certain statins; variations can alter the rate of breakdown, affecting drug levels. Additionally, genes involved in muscle repair and mitochondrial function may influence susceptibility. The clinical significance is that pharmacogenomic testing allows doctors to adjust the drug choice or dose to minimize risk, exemplifying the principles of personalized medicine.